A Targeted Therapeutic for Cancer

AEG35156 is a 2nd generation antisense oligonucleotide which targets XIAP; it is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells. AEG35156 is currently being tested in a randomized Phase 2 combination study with sorafenib in first-line hepatocellular carcinoma being conducted in Hong Kong and a Phase 1/2 monotherapy study in CLL/indolent B-cell lymphomas, which is fully funded by The Leukemia and Lymphoma Society.

July 19, 2010
Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
   
January 26, 2010
Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
   
July 31, 2008
AEGERA INITIATES A FIFTH PHASE 1 and 2 CLINICAL TRIAL FOR AEG35156